Post 5-alpha-reductase inhibitors treatment syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:686468F52.8
Who is this for?
Show terms as
1FDA treatments8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Mar 2026DAYBUE: New indication approved
FDAcompleted
Mar 2023Daybue: FDA approved

treatment of Rett syndrome in adults and pediatric patients 2 years of age and older

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

MAVYRET

glecaprevir and pibrentasvir· AbbVie, Inc.■ Boxed Warning
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor

MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both

No actively recruiting trials found for Post 5-alpha-reductase inhibitors treatment syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Post 5-alpha-reductase inhibitors treatment syndrome community →

No specialists are currently listed for Post 5-alpha-reductase inhibitors treatment syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Daybue

Acadia Pharmaceuticals Inc.

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Post 5-alpha-reductase inhibitors treatment syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Post 5-alpha-reductase inhibitors treatment syndromeForum →

No community posts yet. Be the first to share your experience with Post 5-alpha-reductase inhibitors treatment syndrome.

Start the conversation →

Latest news about Post 5-alpha-reductase inhibitors treatment syndrome

No recent news articles for Post 5-alpha-reductase inhibitors treatment syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Post 5-alpha-reductase inhibitors treatment syndrome

What treatment and support options exist for Post 5-alpha-reductase inhibitors treatment syndrome?

1 patient support program are currently tracked on UniteRare for Post 5-alpha-reductase inhibitors treatment syndrome. See the treatments and support programs sections for copay assistance, eligibility, and contact details.